Drug news
Teva will not file laquinimod at the FDA for Multiple Sclerosis in the immediate future
Teva has announced that it will not be prudent to file laquinimod at the FDA for Multiple Sclerosis in the immediate future. Initial results from the Phase III BRAVO study, the second of two late-stage trials on laquinimod, showed that the drug failed to meet its primary endpoint of reducing the annualised relapse rate when compared with placebo.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.